Nuvectis Pharma, Inc. Financials
This page shows Nuvectis Pharma, Inc. (NVCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash expansion is being financed by new equity, while R&D-heavy losses show a business still funding development from outside capital.
FY2025 ended with$31.6M of cash after a$29.1M financing inflow, so the stronger balance sheet came from fresh capital rather than self-funded operations. That matters because operating cash flow moved from-$12.2M in FY2024 to-$16.0M in FY2025, meaning liquidity improved while cash burn re-accelerated.
The cost base remains development-led: FY2025 R&D was
Balance-sheet strength here is mostly cash on hand, not durable earning power, since cash made up almost all assets at
Financial Health Signals
Nuvectis Pharma, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Nuvectis Pharma, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Nuvectis Pharma, Inc. reported a net loss of $26.4M while operations used $16.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Nuvectis Pharma, Inc. reported -$26.4M in net income in fiscal year 2025. This represents a decrease of 39.2% from the prior year.
Nuvectis Pharma, Inc. earned -$1.32 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 18.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Nuvectis Pharma, Inc. held $31.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Nuvectis Pharma, Inc. paid $0.00 per share in dividends in fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Nuvectis Pharma, Inc.'s ROE was -143.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 52.0 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Nuvectis Pharma, Inc. invested $18.2M in research and development in fiscal year 2025. This represents an increase of 40.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
NVCT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $4.7M+14.1% | $4.1M | N/A | $5.8M+59.8% | $3.6M-1.8% | $3.7M | N/A | $2.8M |
| SG&A Expenses | $2.5M+16.7% | $2.2M | N/A | $2.0M-32.3% | $3.0M+57.9% | $1.9M | N/A | $1.5M |
| Operating Income | -$7.2M-15.0% | -$6.3M | N/A | -$7.8M-18.2% | -$6.6M-18.4% | -$5.6M | N/A | -$4.4M |
| Net Income | -$7.0M-16.0% | -$6.0M | N/A | -$7.5M-17.8% | -$6.3M-18.8% | -$5.3M | N/A | -$4.2M |
| EPS (Diluted) | -$0.30-15.4% | -$0.26+16.1% | -$0.31+29.5% | -$0.44-46.7% | -$0.30-11.1% | -$0.27+25.0% | -$0.36-50.0% | -$0.24 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
NVCT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $22.4M-11.9% | $25.4M-19.9% | $31.7M-10.9% | $35.6M+31.8% | $27.0M-10.4% | $30.1M+62.0% | $18.6M+7.5% | $17.3M |
| Current Assets | $22.4M-11.9% | $25.4M-19.9% | $31.7M-10.9% | $35.6M+31.8% | $27.0M-10.4% | $30.1M+62.0% | $18.6M+7.5% | $17.3M |
| Cash & Equivalents | $22.2M-11.8% | $25.1M-20.6% | $31.6M-10.7% | $35.4M+32.3% | $26.8M-10.3% | $29.9M+61.1% | $18.5M+7.9% | $17.2M |
| Total Liabilities | $13.3M+18.9% | $11.2M-15.9% | $13.3M+14.8% | $11.6M+14.2% | $10.1M+10.2% | $9.2M+3.4% | $8.9M+40.8% | $6.3M |
| Current Liabilities | $13.3M+18.9% | $11.2M-15.9% | $13.3M+14.8% | $11.6M+14.2% | $10.1M+10.2% | $9.2M+3.4% | $8.9M+40.8% | $6.3M |
| Total Equity | $9.1M-36.1% | $14.2M-22.8% | $18.4M-23.3% | $24.0M+42.3% | $16.9M-19.5% | $21.0M+115.7% | $9.7M-11.6% | $11.0M |
| Retained Earnings | -$112.8M-6.6% | -$105.7M-6.1% | -$99.7M-7.9% | -$92.4M-8.8% | -$84.9M-8.1% | -$78.6M-7.3% | -$73.2M-9.3% | -$67.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
NVCT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.5M+30.4% | -$6.5M-63.8% | -$4.0M+11.6% | -$4.5M-33.5% | -$3.4M+19.3% | -$4.2M-69.3% | -$2.5M-2.5% | -$2.4M |
| Investing Cash Flow | N/A | $0 | N/A | N/A | N/A | $0 | N/A | N/A |
| Financing Cash Flow | $1.6M+22200.0% | $7K-95.8% | $166K-98.7% | $13.1M+4340.2% | $296K-98.1% | $15.5M+304.9% | $3.8M+162.8% | $1.5M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
NVCT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -77.3%-34.8pp | -42.5% | N/A | -31.1%+6.5pp | -37.5%-12.1pp | -25.4% | N/A | -37.8% |
| Return on Assets | -31.4%-7.5pp | -23.8% | N/A | -21.0%+2.5pp | -23.4%-5.8pp | -17.7% | N/A | -24.0% |
| Current Ratio | 1.68-0.6x | 2.27-0.1x | 2.38-0.7x | 3.07+0.4x | 2.66-0.6x | 3.28+1.2x | 2.09-0.6x | 2.74 |
| Debt-to-Equity | 1.46+0.7x | 0.79+0.1x | 0.72+0.2x | 0.48-0.1x | 0.60+0.2x | 0.44-0.5x | 0.92+0.3x | 0.57 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Nuvectis Pharma, Inc. Ranks
Frequently Asked Questions
Is Nuvectis Pharma, Inc. profitable?
No, Nuvectis Pharma, Inc. (NVCT) reported a net income of -$26.4M in fiscal year 2025.
What is Nuvectis Pharma, Inc.'s return on equity (ROE)?
Nuvectis Pharma, Inc. (NVCT) has a return on equity of -143.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nuvectis Pharma, Inc.'s operating cash flow?
Nuvectis Pharma, Inc. (NVCT) recorded an outflow of $16.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Nuvectis Pharma, Inc.'s total assets?
Nuvectis Pharma, Inc. (NVCT) had $31.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Nuvectis Pharma, Inc. spend on research and development?
Nuvectis Pharma, Inc. (NVCT) invested $18.2M in research and development during fiscal year 2025.
What is Nuvectis Pharma, Inc.'s current ratio?
Nuvectis Pharma, Inc. (NVCT) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.
What is Nuvectis Pharma, Inc.'s debt-to-equity ratio?
Nuvectis Pharma, Inc. (NVCT) had a debt-to-equity ratio of 0.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nuvectis Pharma, Inc.'s return on assets (ROA)?
Nuvectis Pharma, Inc. (NVCT) had a return on assets of -83.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Nuvectis Pharma, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Nuvectis Pharma, Inc. (NVCT) held $31.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.0M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Nuvectis Pharma, Inc.'s Piotroski F-Score?
Nuvectis Pharma, Inc. (NVCT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nuvectis Pharma, Inc.'s earnings high quality?
Nuvectis Pharma, Inc. (NVCT) reported a net loss of $26.4M while operations used $16.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.